Quantcast

Latest neutropenia Stories

2010-10-26 13:57:00

PALO ALTO, Calif., Oct. 26 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) announced today that Telintra (Ezatiostat HCl), the company's lead therapeutic product candidate, has been selected by Windhover Information and its advisors as one of "The Top 10 Most Interesting Oncology Projects to Watch." Windhover is a leading provider of business information to senior executives in the pharmaceutical, biotechnology, and medical device industries. The company has been invited to present at...

2010-10-01 07:00:00

BRIDGEWATER, N.J., Oct. 1 /PRNewswire-FirstCall/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that data from the Phase III TROPIC study, which was the basis for the June 2010 U.S. Food and Drug Administration (FDA) approval of Jevtana® (cabazitaxel) Injection, was published in the October 2, 2010 print edition of The Lancet in an article titled "Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing...

2010-09-26 16:00:00

MELBOURNE, Australia, Sept. 26 /PRNewswire-FirstCall/ -- Hospira, Inc. (NYSE: HSP), the world leader in generic injectable pharmaceuticals, today announced that it has received Australian Therapeutic Goods Administration (TGA) approval for its biosimilar filgrastim product, Nivestim(TM). Nivestim has been approved for a range of indications, including the prevention of febrile neutropenia (FN) and reduction in duration of chemotherapy-induced neutropenia (CIN). Neutropenia is the most...

2010-08-05 07:00:00

BRIDGEWATER, N.J., Aug. 5 /PRNewswire/ -- Sanofi-aventis U.S. announced today that the U.S. Food and Drug Administration (FDA) has approved a new one-vial formulation of its chemotherapeutic agent Taxotere® (docetaxel) Injection Concentrate. The 1-vial Taxotere is anticipated to become available to cancer treatment clinics and hospitals nationwide in the fall in both 80 mg and 20 mg dosages. Introduced more than 14 years ago, Taxotere is approved by the FDA for use in...

2010-06-17 14:40:00

PARIS, June 17 /PRNewswire-FirstCall/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the U.S. Food and Drug Administration (FDA) has granted marketing authorization for Jevtana® (cabazitaxel) Injection in combination with prednisone for the treatment of patients with metastatic hormone-refractory prostate cancer (mHRPC) previously treated with a docetaxel-containing treatment regimen. Jevtana, a microtubule inhibitor, in combination with prednisone...

2010-06-10 08:45:00

LEAMINGTON SPA, United Kingdom, June 10 /PRNewswire-FirstCall/ -- Hospira announced today that the EC has approved Nivestim(TM) (filgrastim) for the prevention of FN, the most serious haematological toxicity that occurs as a result of cancer chemotherapy(1). Nivestim now has marketing authorisation in all EU member states. Nivestim is expected to reduce the cost of neutropenia treatment. Dr Cornelius Waller, Associate Professor of Internal Medicine at the Freiburg University Medical...

2010-06-06 11:30:00

CHICAGO, June 6 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced positive results from a Phase 2 clinical study evaluating single-agent NKTR-102 in women with platinum-resistant/refractory ovarian cancer. A total of 68 patients were enrolled with platinum-resistant disease, half of whom were platinum refractory. All 68 patients were evaluable for the primary endpoint of objective response rate using Gynecologic Cancer InterGroup (GCIG) criteria, which is a...

2010-03-11 22:00:00

WOODCLIFF LAKE, N.J., March 11 /PRNewswire-FirstCall/ -- Eisai Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a five-day dosing regimen for Dacogen® (decitabine) for Injection to treat patients with myelodysplastic syndromes (MDS), a group of bone marrow diseases that alter the production of functional blood cells. The new outpatient dosing option provides physicians and patients with the flexibility of a dosing regimen with a reduced...

2010-03-10 12:13:34

Multicenter trial led by St. Jude Children's Research Hospital investigators may change neutropenia treatment for all childhood cancer patients For patients like 10-year-old Sabrina Jo Spence, new research led by St. Jude Children's Research Hospital investigators meant fewer injections to combat the drop in white blood cells following her recent chemotherapy. "Cool," Sabrina told Sheri Spunt, M.D., an associate member of the St. Jude Department of Oncology, after hearing the news and...

2009-09-10 08:00:00

LOS ANGELES, Sept. 10 /PRNewswire/ -- Award-winning actresses Edie Falco and Cynthia Nixon appear in a new Stand Up To Cancer(TM) (SU2C) public service campaign to educate cancer patients and their loved ones about the increased risk of infection during cancer treatment and the importance of learning how to manage one's risk. To view the Multimedia News Release, go to: http://www.prnewswire.com/mnr/amgen/39907/ (Photo: http://www.newscom.com/cgi-bin/prnh/20090910/NY73333 ) Often...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related